News Real world data will help AZ's Farxiga in cardio battle AZ hopes data will boost sales of its Farxiga.
Views & Analysis Precision medicine and data science: the ‘new normal’ for dr... Balancing innovation and huge unmet patient need with burgeoning cost constraints.
News Lilly/Boehringer diabetes combos get cardio data boost Lilly/Boehringer gain further advantage in US diabetes market.
News Lilly and Boehringer biosimilar undercuts Lantus by 15% Sanofi under pressure following long-awaited biosimilar launch.
News Five UK pharma companies "named and shamed" by watchdog Companies' actions discredited the industry, says PMCPA.
News Lilly/Boehringer's long-acting diabetes pill approved in US Long-release pill is eighth drug to come from diabetes partnership.
News Relief for AZ as Truqap hits the spot in prostate cancer After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
